Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

138Citations
Citations of this article
119Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: In this article, we present a comparative immunohistochemical evaluation of four clinical-stage antibodies (L19, F16, G11 and F8) directed against splice isoforms of fibronectin and of tenascin-C for their ability to stain synovial tissue alterations in rheumatoid arthritis patients. Furthermore we have evaluated the therapeutic potential of the most promising antibody, F8, fused to the anti-inflammatory cytokine interleukin (IL) 10.Methods: F8-IL10 was produced and purified to homogeneity in CHO cells and shown to comprise biological active antibody and cytokine moieties by binding assays on recombinant antigen and by MC/9 cell proliferation assays. We have also characterized the ability of F8-IL10 to inhibit arthritis progression in the collagen-induced arthritis mouse model.Results: The human antibody F8, specific to the extra-domain A of fibronectin, exhibited the strongest and most homogenous staining pattern in synovial biopsies and was thus selected for the development of a fully human fusion protein with IL10 (F8-IL10, also named DEKAVIL). Following radioiodination, F8-IL10 was able to selectively target arthritic lesions and tumor neo-vascular structures in mice, as evidenced by autoradiographic analysis and quantitative biodistribution studies. The subcutaneous administration route led to equivalent targeting results when compared with intravenous administration and was thus selected for the clinical development of the product. F8-IL10 potently inhibited progression of established arthritis in the collagen-induced mouse model when tested alone and in combination with methotrexate. In preparation for clinical trials in patients with rheumatoid arthritis, F8-IL10 was studied in rodents and in cynomolgus monkeys, revealing an excellent safety profile at doses tenfold higher than the planned starting dose for clinical phase I trials.Conclusions: Following the encouraging preclinical results presented in this paper, clinical trials with F8-IL10 will now elucidate the therapeutic potential of this product and whether the targeted delivery of IL10 potentiates the anti-arthritic action of the cytokine in rheumatoid arthritis patients. © 2009 Schwager et al.; licensee BioMed Central Ltd.

References Powered by Scopus

Dose translation from animal to human studies revisited

5146Citations
N/AReaders
Get full text

Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

1519Citations
N/AReaders
Get full text

Multiplexed particle-based flow cytometric assays

833Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Interfering with pH regulation in tumours as a therapeutic strategy

1395Citations
N/AReaders
Get full text

IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation

734Citations
N/AReaders
Get full text

ImmunoPET: Concept, Design, and Applications

334Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Schwager, K., Kaspar, M., Bootz, F., Marcolongo, R., Paresce, E., Neri, D., & Trachsel, E. (2009). Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Research and Therapy, 11(5). https://doi.org/10.1186/ar2814

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 49

60%

Researcher 29

35%

Professor / Associate Prof. 4

5%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 28

36%

Agricultural and Biological Sciences 26

33%

Medicine and Dentistry 14

18%

Immunology and Microbiology 10

13%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free